Cargando…
Gabapentin—Friend or foe?
BACKGROUND: Gabapentin is a recommended first‐line agent for treating neuropathic pain; however, its efficacy rate is reportedly low, and the risk of adverse events is high. A plausible explanation for this lies with its wide range of actions, the entirety of which have yet to be fully elucidated. M...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092611/ https://www.ncbi.nlm.nih.gov/pubmed/36300903 http://dx.doi.org/10.1111/papr.13165 |